Gilead Sciences Inc (GILD)

GILD (NASDAQ:Drugs) EQUITY
$79.77
pos +0.00
+0.00%
Today's Range: 79.27 - 80.33 | GILD Avg Daily Volume: 10,180,700
Last Update: 08/26/16 - 4:00 PM EDT
Volume: 0
YTD Performance: -21.17%
Open: $0.00
Previous Close: $80.08
52 Week Range: $77.92 - $113.31
Oustanding Shares: 1,319,658,489
Market Cap: 105,678,251,799
6-Month Chart
TheStreet Ratings Grade for GILD
Buy Hold Sell
A+ A A- B+ B B- C+ C C- D+ D D- E+ E E- F
TheStreet Ratings is the source for accurate ratings that you can rely upon to make sound, informed financial decisions. Click here to find out about our methodology.
Analysts Ratings
Historical Rec Current 1 Mo. Ago 2 Mo. Ago 3 Mo. Ago
Strong Buy 8 8 8 8
Moderate Buy 1 1 2 2
Hold 9 8 7 7
Moderate Sell 0 0 0 0
Strong Sell 0 0 0 0
Mean Rec. 2.06 2.00 1.94 1.94
Latest Dividend: 0.47
Latest Dividend Yield: 2.35%
Dividend Ex-Date: 09/14/16
Price Earnings Ratio: 7.06
Price Earnings Comparisons:
GILD Sector Avg. S&P 500
7.06 6.70 12.90
Price Performance History (%Change):
3 Mo 1 Yr 3 Y
-6.47% -25.42% 32.03%
GROWTH 12 Mo 3 Yr CAGR
Revenue 31.10 2.40 0.49
Net Income 50.10 6.00 0.90
EPS 62.00 6.20 0.92
Earnings for GILD:
EBITDA 23.29B
Revenue 32.64B
Average Earnings Estimates
Qtr (09/16) Qtr (12/16) FY (12/16) FY (12/17)
Average Estimate $2.79 $2.75 $11.53 $11.58
Number of Analysts 8 6 10 6
High Estimate $3.03 $3.01 $12.02 $13.03
Low Estimate $2.57 $2.49 $10.92 $10.57
Prior Year $3.19 $3.27 $12.45 $11.53
Growth Rate (Year over Year) -12.66% -15.85% -7.42% 0.47%
Chart Benchmark
Average Frequency Timeframe
Indicator Chart Scale  
Symbol Comparison Bollinger Bands
Stocks are back to flat to slightly lower overall, but biotechs are up some 1.5% following the announcement from Pfizer (PFE) of plans to buy Medivation (MDVN) for $14 billion.
RBC Capital analysts say splitting the company into two distinct businesses would free 'trapped value' on drug treatments.
There is a case for a low already being in place.
Rarely do investors get to buy these types of quality businesses at such discounted prices.
With enough of earnings season now under our belt, we check out the promising themes and the sectors to avoid.
The sector seems to be rebounding after tumbling by more than 40%.
That may be the best way to get through the notorious month of August.

Today's Good, Bad and Ugly Real Money Pro($)

Market continues to run like the Energizer Bunny, completing a very strong month of July. Gold continues to shine following the weak second-quarter GDP print, which implies "lower for longer" and more cowbell from the world's central bankers. . Staples, excluding Coca-Cola (KO) , that are benefiting from a weak currency have revived today. The two pillars of technology -- Amazon (AMZN) and Alphabet (GOOGL) -- ring the register for investors. This is aiding PowerShares QQQ ETF's (QQQ) absolute and relative strength vis a vis the other indices. Herbalife (HLF) continues to rally after its agreement with authorities. Or maybe Ackman/Pershing Square is just getting squeezed by Carl Icahn! Schlumberger (SLB) , despite only a modest rise in crude oil today (after crude was down 17% for month of July) , is a standout. To many, Twitter (TWTR) is showing surprising strength --up 2% today -- following Thursday's drubbing. I added small on Thursday and in the after-hours on Wednesday. I like the upside/downside but I have no illusion that the near-term outlook is promising as management's heavy lifting lies ahead, and it will take time. A multi-month high for Blackstone/GSO Strategic Credit Fund (BGB) despite a nearly 20% drop in the price of crude oil this month. The Bad Domestic growth is weak, with 2Q real GDP up 1.2% -- well short of expectations. Gilead Sciences (GILD) , a favorite value play in biotech, continues to fall, breaking $80 a share. Talking head "carpet sweepers" are nowhere to be seen on this one!. Life insurance stocks, plagued by the absence of investing alternatives in a low-rate setting, continue to weaken. Potash (POT) continues to sell off after weak top-line performance and poor forward guidance. I reviewed the quarter this morning. The Ugly My long Hartford Financial Services Group (HIG) , my project this weekend, is stinking up the joint after an earnings shortfall caused by catastrophe losses and a weak auto book. My preliminary read is that there

The Good, The Bad and The Ugly Real Money Pro($)

Apple (AAPL) . Apple's earnings beat expectations, and I've shorted more of the stock today. Banks. Financials continue to inch higher despite the flattening yield curve (which I addressed yesterday). Bank of America (BAC) , Citigroup (C) and JPMorgan Chase (JPM) are all marginally higher today amid a weak tape. However, I'm not currently playing in the sector. The Nasdaq Composite. With Apple at the index's back, the Nasdaq Composite continues to climb. Gold. The precious metal has successfully approached and tested the $1,300 breakout level. Junk bonds. High-yield continues a multi-month-long rally. The Blackstone/GSO Strategic Credit closed-end fund (B
It's too cheap for a biotech giant with years of patent protection for its key products and great cash flow.

Columnist Conversations

The dollar index ended up holding support nicely into both the time and price parameters discussed last ...

REAL MONEY'S BEST IDEAS

News Breaks

Powered by

BROKERAGE PARTNERS

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data provided by Interactive Data. Company fundamental data provided by Morningstar. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by Interactive Data Managed Solutions.


TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

IDC calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.